Columbia Laboratories is leveraging its rich heritage as a pharmaceutical research and development organization to become a leading women's healthcare company. We will achieve this goal by increasing market share of our current products while developing new products for Columbia and our strategic partners using our novel Bioadhesive Delivery System (BDS).
Expanding our Commercial Presence
We are focused on maximizing the return from our progesterone products in the United States through direct promotion to reproductive endocrinologists, obstetricians and gynecologists. To generate additional revenue from our products, we have entered into licensing agreements with marketing partners to sell our products in markets around the world and in U.S. markets that fall outside our strategic focus.
Developing New Indications
Two of our currently marketed products are being studied for potential new indications. Our lead opportunity is PROCHIEVEŽ 8% (progesterone gel) to reduce the risk of preterm birth in women with a short cervix. A third-party is conducting a long-term study of PROCHIEVEŽ 4% (progesterone gel) for the prevention of endometrial hyperplasia in women with an intact uterus who receive estrogen as part of a Hormone Replacement Therapy (HRT) regimen.
Developing New Products
We continue to explore new applications for our BDS technology. There are many promising products in our development pipeline as well as licensing opportunities to apply BDS to strategic partners' compounds to address indications outside our therapeutic areas of focus. |
|